ArticleCancer imaging : the official publication of the International Cancer Imaging Society2013
Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Comparison of diffusion-weighted MRI and [European radiology · 2024Review
- Whole-body diffusion-weighted MRI in lymphoma-comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals.Quantitative imaging in medicine and surgery · 2021Article
- Whole-Body Magnetic Resonance Imaging: Current Role in Patients with Lymphoma.Diagnostics (Basel, Switzerland) · 2021Review
- A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.Radiology. Imaging cancer · 2021Article
- What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century.The British journal of radiology · 2020Review
- MRI and PET/MRI in hematologic malignancies.Journal of magnetic resonance imaging : JMRI · 2020Review
- Ultra-early response assessment in lymphoma treatment: [European journal of nuclear medicine and molecular imaging · 2018Article
- Diffusion MRI in early cancer therapeutic response assessment.NMR in biomedicine · 2017Review
- Whole-body MRI in patients with lymphoma: collateral findings.La Radiologia medica · 2016Article
- Role of WB-MR/DWIBS compared to (18)F-FDG PET/CT in the therapy response assessment of lymphoma.La Radiologia medica · 2016Article
- Article
- Assessment of chemotherapy response in non-Hodgkin lymphoma involving the neck utilizing diffusion kurtosis imaging: a preliminary study.Diagnostic and interventional radiology (Ankara, Turkey)Article
- The Role of Whole-Body MRI in Patients with Lymphoma: A Narrative Review.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate 3 Tesla (T) whole-body diffusion-weighted magnetic resonance imaging (WB DWI) for early treatment assessment in aggressive non-Hodgkin lymphoma (NHL).
methodsFourteen patients with NHL treated with standard chemotherapy underwent 3-T WB DWI before and 2 and 4 weeks during treatment, using b-values of 0-1000 s/mm(2) from which the apparent diffusion coefficient (ADC) was calculated. Patient follow-up (average 20.3 months, range 15-23 months) was the reference standard. Volume and ADC changes between baseline and 2 weeks (Vratio2w, ADCratio2w) and 4 weeks (Vratio4w, ADCratio4w) of responding and non-responding lesions (lymph node and organ lesions) were compared using Mann-Whitney U tests. The per patient values of VratioN and ADCratioN to predict progression-free survival were determined with a log-rank test.
resultsEight patients showed complete remission and 6 showed tumour progression. The ADCratio2w and ADCratio4w differed significantly in lesions showing tumour progression versus complete remission (ADCratio2w = 4 ± 21% versus 119 ± 68%; ADCratio4w = 18 ± 61% versus 155 ± 78%; both P < 0.0001); the Vratio2w and Vratio4w did not (P > 0.05). Per body region, the ADCratio2w showed a negative predictive value of 100% and positive predictive value of 86%. Per patient, the ADCratio2w and ADCratio4w correlated significantly with progression-free survival (P < 0.05).
conclusion3-T WB DWI with ADC quantification may enable early treatment assessment of aggressive NHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.